Diffuse large B-cell lymphoma in the elderly: Diffusion of treatment with rituximab and survival advances with and without anthracyclines

Leukemia and Lymphoma

Volumn 52, Issue 6, 2011, Pages 994-1002

  Link, Brian K ^a,b,c   Brooks, John ^c   Wright, Kara ^c   Pan, Xiaoyun ^c   Voelker, Margaret ^c   Chrischilles, Elizabeth ^a,c  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

elderly; immunotherapy; Non Hodgkin lymphoma; survival

Indexed keywords

ANTHRACYCLINE DERIVATIVE; RITUXIMAB;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; FEMALE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MULTIVARIATE ANALYSIS; PROGNOSIS; SEER PROGRAM; TREATMENT OUTCOME;

EID: 79956353648     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.557167     Document Type: Article

References (18)

1. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe dEtude des Lymphomes de lAdulte. JClin Oncol 2005;23:4117-4126. (Pubitemid 46211317)
2. Habermann TM, Weller EA, Morrison VA, et al. Rituximab- CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-3127. (Pubitemid 46638950)
3. Grann VR, Hershman D, Jacobson JS, et al. Outcomes and diffusion of doxorubicin-based chemotherapy among elderly patients with aggressive non-Hodgkin lymphoma. Cancer 2006;107:1530-1541. (Pubitemid 44546914)
4. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-2833. (Pubitemid 28363048)
5. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti- CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92:1927-1932. (Pubitemid 28446681)
6. Link BK, Grossbard ML, Fisher RI, et al. Phase II pilot study of the safety and efficacy of rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate- or high-grade NHL. Proc Am Soc Clin Oncol 1998;17: Abstract 7.
7. Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkins lymphoma. J Clin Oncol 2001;19:389-397. (Pubitemid 32112850)
8. Coiffier B, Lepage E, Herbrecht R, et al. Rituximab plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma: interim results of a randomized GELA study. Blood 2000;96(Suppl. 1): Abstract 950.
9. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346: 235-242. (Pubitemid 34438862)
10. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027-5033. (Pubitemid 46224009)
11. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 1993;31:732-748.
12. Warren JL, Harlan LC, Fahey A, et al. Utility of the SEERMedicare data to identify chemotherapy use. Med Care 2002;40(8 Suppl.):IV55-IV61.
13. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40: 373-383. (Pubitemid 17055592)
14. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53:1258-1267. (Pubitemid 32007842)
15. Sonneveld P, de Ridder M, van der Lelie H, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkins lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995;13:2530-2539.
16. Best JH, Hornberger J, Proctor SJ, Omnes LF, Jost F. Costeffectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma. Value Health 2005;8:462-470. (Pubitemid 41726099)
17. Groot MT, Lugtenburg PJ, Hornberger J, Huijgens PC, Uylde Groot CA. Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands. Eur J Haematol 2005;74:194-202. (Pubitemid 40278488)
18. Hornberger JC, Best JH. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer 2005;103:1644-1651. (Pubitemid 40490025)